Results 81 to 90 of about 1,937,987 (265)

Emerging Therapies in Immune Thrombocytopenia

open access: yesJournal of Clinical Medicine, 2021
Immune thrombocytopenia (ITP) is a rare autoimmune disorder caused by peripheral platelet destruction and inappropriate bone marrow production. The management of ITP is based on the utilization of steroids, intravenous immunoglobulins, rituximab ...
S. Audia, B. Bonnotte
semanticscholar   +1 more source

A likely unavoidable clinical scenario during treatment for venous thromboembolism complicated with severe immune thrombocytopenia: A case report

open access: yesClinical Case Reports, 2021
Patients with immune thrombocytopenia have increased risks of bleeding and thrombosis. The acute‐phase treatment for venous thromboembolism complicated with severe immune thrombocytopenia involves a “platelet dilemma” in therapeutic decision‐making.
Takaya Takeuchi   +11 more
doaj   +1 more source

Human Inborn Errors of Immunity: 2019 Update of the IUIS Phenotypical Classification. [PDF]

open access: yes, 2020
Since 2013, the International Union of Immunological Societies (IUIS) expert committee (EC) on Inborn Errors of Immunity (IEI) has published an updated phenotypic classification of IEI, which accompanies and complements their genotypic classification ...
Ailal, Fatima   +18 more
core  

Management of Adult Patients with Immune Thrombocytopenia (ITP): A Review on Current Guidance and Experience from Clinical Practice

open access: yesJournal of Blood Medicine, 2021
Immune thrombocytopenia (ITP) is an autoimmune process resulting in increased destruction and inadequate production of platelets that can result in bleeding, fatigue, and reduced health-related quality of life.
Fei Song, Hanny Al-Samkari
semanticscholar   +1 more source

Recognition and Clinical Presentation of Invasive Fungal Disease in Neonates and Children [PDF]

open access: yes, 2017
AW and JK are supported by the Wellcome Trust Strategic Award (grant 097377) and the MRC Centre for Medical Mycology (grant MR/N006364/1) at the University of AberdeenPeer reviewedPublisher ...
King, Jill   +4 more
core   +1 more source

Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia.

open access: yesBlood Advances, 2020
Primary immune thrombocytopenia (ITP) is a predominantly immunoglobulin G (IgG)-autoantibody-mediated disease characterized by isolated thrombocytopenia.
T. Robak   +13 more
semanticscholar   +1 more source

Kasabach-Merritt syndrome arising from an Enteroatmospheric Fistula [PDF]

open access: yesarXiv, 2022
Kasabach-Merritt syndrome (KMS) is a rare, life-threatening condition that is characterized by profound thrombocytopenia, hypofibrinogenemia, elevated partial thromboplastin time, and may also be associated with microangiopathic hemolytic anemia. It is well established that this phenomenon is notably associated with the vascular tumors kaposiform ...
arxiv  

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. [PDF]

open access: yes, 2017
Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of immune-based therapies, including the widely used class of agents known as immune checkpoint inhibitors, has exposed a discrete group of immune-related adverse ...
Abdallah, K.   +80 more
core   +2 more sources

T cell–mediated autoimmunity in immune thrombocytopenia

open access: yesEuropean Journal of Haematology, 2021
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a low platelet count and an increased risk of bleeding. In addition to anti‐platelet autoantibodies, CD8+ T cells have been implicated as a mechanism of platelet destruction.
J. Vrbensky   +4 more
semanticscholar   +1 more source

International consensus report on the investigation and management of primary immune thrombocytopenia.

open access: yesBlood, 2010
Previously published guidelines for the diagnosis and management of primary immune thrombocytopenia (ITP) require updating largely due to the introduction of new classes of therapeutic agents, and a greater understanding of the disease pathophysiology ...
D. Provan   +21 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy